HOME >> BIOLOGY >> NEWS
Rimonbant shows promise in addressing multiple risk factors

reduced plasma insulin levels and the changed size of LDL particles, we now may have a drug that targets the most frequent cause of clustering risk factors."

RIO LIPIDS FINDINGS

A multi-center, double-blind, placebo-controlled study, RIO-Lipids enrolled 1,036 obese patients with dyslipidemia and a BMI between 27 and 40 kg/m2. Patients were randomized into three treatment groups receiving either a daily, fixed dose of 5mg or 20mg of rimonabant or placebo along with a reduced calorie diet for one year.

Patients treated for one year with rimonabant 20mg lost almost 20 lbs (8.6 kg) vs. a loss of only 5 lbs (2.4 kg) on placebo (p<0.001). Nearly three-fourths (72.9%) of these patients treated for a year with rimonabant 20mg lost more than 5% of their body weight vs. placebo (p<0.001) while nearly half (44.3%) lost in excess of 10% of their body weight vs. placebo (p<0.001). While weight loss was the primary endpoint, a waist circumference reduction of 3.4 inches (9.1 cm) in patients completing a year of treatment on rimonabant 20 mg was statistically significant (p<0.001 vs. placebo).

Researchers also designed the RIO-Lipids study to determine if rimonabant, in a group of overweight/obese patients at risk for cardiovascular disease, could improve important factors such as lipid profile, glucose metabolism and other features of the metabolic syndrome. Results show that both the 5 mg and 20 mg doses of rimonabant significantly improved two important indicators of cardiovascular risk, HDL-cholesterol and triglycerides vs. placebo. The patients treated for a year in the 20 mg group achieved an average 23% increase (p<0. 001 vs. placebo) in HDL-cholesterol and a reduction of 15% in triglycerides (p<9x10-5 vs. placebo).

No difference in LDL-cholesterol was observed between rimonabant and placebo. However, rimonabant 20mg delivered positive changes in LDL particle size, a known indicator of atherogenic risk. In patient
'"/>

Contact: Glenn Lehrman
glenn.lehrman@ketchum.com
917-533-5998
Ketchum
9-Mar-2004


Page: 1 2 3 4 5 6

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/2/2017)... MELBOURNE, Australia , March 2, 2017 ... Therapeutics Ltd (ASX: CYP), has signed an agreement ... researchers from the Monash Biomedicine Discovery Institute and Department ... , to conduct a further preclinical study to support ... the treatment of asthma.  Asthma is ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... 28, 2017 Dr. Chris Yu ... corporation Anpac Bio-Medical Science Company , announced ... record, processing and reporting over 40,000 cases worldwide ... (CDA) liquid biopsy tests. Described ... Summit publications, Anpac Bio,s CDA medical devices and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for Parkinson’s ... study published in STEM CELLS suggests that human neural stem cell (hNSC) transplantation ... produce more neural cells. , Strategies involving transplantation of these cells into ...
(Date:3/28/2017)... 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) ... safety and clinical data from its phase 1/2 tendon repair ... follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The ... profile at 6 months and showed no serious adverse events ...
(Date:3/27/2017)... , March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ... solutions for the detection of foodborne pathogens,  today announced that ... & Company Spring 2017 Convention on March 29 at 9:50am ... Marriott Marquis. About Roka Bioscience ... Roka Bioscience ...
Breaking Biology Technology:
Cached News: